%PDF-1.4
%
70 0 obj
<>
endobj
67 0 obj
<>
endobj
171 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-12-09T11:50:49Z
2024-03-28T23:29:16-07:00
QuarkXPressª: AdobePS 8.8.0 (301)
2024-03-28T23:29:16-07:00
application/pdf
Heather
2004-146.jan
uuid:8d55c827-1dd2-11b2-0a00-250a276d7200
uuid:8d55c82a-1dd2-11b2-0a00-b80000000000
endstream
endobj
56 0 obj
<>
endobj
57 0 obj
<>
endobj
71 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 40 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 42 0 R/Type/Page>>
endobj
4 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 44 0 R/Type/Page>>
endobj
7 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 46 0 R/Type/Page>>
endobj
26 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 48 0 R/Type/Page>>
endobj
29 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 50 0 R/Type/Page>>
endobj
198 0 obj
[203 0 R]
endobj
199 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
13.5 787.5 585 -783 re
W n
q
0 792.03 612 -792 re
W n
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 61 736.1941 Tm
[(6.)-875 (Jaeschke R, Singer J, Guyatt G. Measurement of health status.)]TJ
1.675 -1.25 Td
[(Ascertaining the minimal clinically important dif)18 (ference. Control)]TJ
0.00729 Tw 0 -1.25 TD
[(Clin T)35 (rials )-18 (1989;10:407-15.)]TJ
0.02499 Tw -1.675 -1.25 Td
[(7.)-875 (W)80 (ells G, Beaton D, Shea B. Minimal clinically important )]TJ
1.675 -1.25 Td
[(dif)18 (ferences: Review of methods. J Rheumatol 2001;28:406-12.)]TJ
-1.675 -1.25 Td
[(8.)-875 (W)80 (ells G, )55 (Anderson J, Beaton D. Minimal clinically important )]TJ
1.675 -1.25 Td
[(dif)18 (ferences module: Summary)65 (, recommendations, and research)]TJ
T*
(agenda. J Rheumatol 2001;28:452-5.)Tj
-1.675 -1.25 Td
[(9.)-875 (Stratford PW)92 (, Binkley JM, Riddle DL, Guyatt GH. Sensitivity to)]TJ
1.675 -1.25 Td
[(change of the Roland-Morris Back Pain Questionnaire. Phys )18 (Ther)]TJ
0 Tc 0 Tw T*
[(1998;1)37 (1:1)37 (186-207.)]TJ
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(10.)-875 (Felson DT)74 (, )55 (Anderson JJ. )55 (A)-220 (review of evidence on the discriminant)]TJ
2.175 -1.25 Td
(validity of outcome measures in rheumatoid arthritis. J Rheumatol)Tj
0 Tc 0 Tw T*
(2001;28:422-6.)Tj
-0.00011 Tc 0.02499 Tw -2.1381 -1.25 Td
[(1)37 (1.)-875 (Cranney )55 (A, )18 (W)80 (elch )18 (V)129 (, )18 (W)80 (ells G, et al. Discrimination of changes in)]TJ
2.1381 -1.25 Td
(osteoporosis outcomes. J Rheumatol 2001;28:413-21.)Tj
-2.175 -1.25 Td
[(12.)-875 (Ravaud P)111 (, Giraudeau B, )55 (Audeley R, Edouard-Noel R, Dougados M,)]TJ
2.175 -1.25 Td
[(Chastang C. )55 (Assessing smallest detectable change over time in )]TJ
T*
[(continuous structural outcome measures: )55 (Application to )]TJ
T*
(radiological change in knee osteoarthritis. J Clin Epidemiol)Tj
0 Tc 0 Tw T*
(1999;52:1225-30.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(13.)-875 (V)111 (an der Linden S, )18 (V)111 (alkenbur)18 (g H, Cats )55 (A. Evaluation of diagnostic)]TJ
2.175 -1.25 Td
(criteria for ankylosing spondylitis, a proposal for modification of)Tj
T*
[(the New )37 (Y)100 (ork criteria. )55 (Arthritis Rheum 1984;27:361-8.)]TJ
30.825 28.75 Td
[(14.)-875 (W)80 (olfe F)80 (. Comparative usefulness of C-reactive protein and )]TJ
2.175 -1.25 Td
(erythrocyte sedimentation rate in patients with RA. J Rheumatol)Tj
0 Tc 0 Tw T*
(1997;24:1477-85.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(15.)-875 (Juniper E, Guyatt G, )18 (W)40 (illan )55 (A, Grif)18 (fith L. Determining a minimal)]TJ
2.175 -1.25 Td
(important change in a disease-specific quality of life questionnaire.)Tj
T*
(J Clin Epidemiol 1994;47:81-7.)Tj
-2.175 -1.25 Td
[(16.)-875 (Beaton DE, Boers M, )18 (W)80 (ells GA. Many faces of the minimal )]TJ
2.175 -1.25 Td
[(clinically important dif)18 (ference \(MCID\): a literature review and)]TJ
T*
(directions for future research. Curr Opin Rheumatol )Tj
0 Tc 0 Tw T*
(2002;14:109-14.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(17.)-875 (Norman GR, Stratford PW)92 (, Regehr G. Methodological problems in)]TJ
2.175 -1.25 Td
(the retrospective computation of responsiveness to change: the )Tj
T*
(lesson of Cronbach. J Clin Epidemiol 1997;50:869-79.)Tj
-2.175 -1.25 Td
[(18.)-875 (T)35 (ugwell P)111 (, Bombardier C, Buchanan )18 (W)92 (, Goldsmith C, Grace E,)]TJ
2.175 -1.25 Td
[(Hanna B. )18 (The MACT)80 (AR Patient Preference Disability)]TJ
T*
(Questionnaire: an individualized functional priority approach for)Tj
T*
(assessing improvement in physical disability in clinical trials in)Tj
T*
(rheumatoid arthritis. J Rheumatol 1987;14:446-51.)Tj
-2.175 -1.25 Td
[(19.)-875 (Linton SJ, Melin L. )18 (The accuracy of remembering chronic pain.)]TJ
2.175 -1.25 Td
(Pain 1982;13:281-5.)Tj
-2.175 -1.25 Td
[(20.)-875 (Dougados M, B\216hier JM, Jolchine I, et al. Ef)18 (ficacy of celecoxib in)]TJ
2.175 -1.25 Td
[(the treatment of ankylosing spondylitis. )55 (Arthritis Rheum)]TJ
0 Tc 0 Tw T*
(2001;44:180-5.)Tj
ET
0 0 0 1 K
53.468 76.5 m
558.468 76.5 l
S
0 0 0 0 k
494.29 69.365 64.178 -15.665 re
f*
BT
0 0 0 1 k
/T1_1 1 Tf
8 0 0 8 549.468 56.4344 Tm
(85)Tj
ET
0 0 0 0 k
53.532 70.504 203 -16.734 re
f*
BT
0 0 0 1 k
/T1_1 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 54.532 56.504 Tm
[(Pavy)55 (, et al: )18 (Ankylosing spondylitis indices)]TJ
ET
0 0 0 0 k
/GS0 gs
103.782 80.583 407.5 -10.833 re
f*
0.5 w
/GS1 gs
103.782 80.583 407.5 -10.833 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 g
ET
/GS2 gs
BT
/T1_2 8 Tf
106.328 74 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2005. All rights reserved.)Tj
ET
Q
BT
0 g
/GS3 gs
/T1_3 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS3 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS3 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
50 0 obj
<>stream
8;Z\5m;<"\#ikkjOOmXc@%1E2ANMdH0k")4og0+TO17.J'?jdTf2k)I?TB5,r@i]9
Aj!V(AGFM,rb:j\<2JF`X?Mis)SQb[%[L(P@;uWeq*MTsTjfH!RlJ.8D+g%XHRCJ>ofCH*EucjAUVg!KfrG3Fr6e.*,Q&Ptn?-dJeSYc-64_o[kpH.R6=8V
endstream
endobj
54 0 obj
[/Indexed/DeviceRGB 255 53 0 R]
endobj
53 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
85 0 obj
<>
endobj
73 0 obj
<>
endobj
109 0 obj
<>
endobj
177 0 obj
<>
endobj
74 0 obj
<>
endobj
100 0 obj
<>stream
HiPSYey&qRni[ٺY"D $, "d
,*8Kݍ0Z36UjyKL25eVu=Sunj0-w\%1Iw*#Ɓ`V;GF7%.3VhM:.-Mp~9̘5;c$s[OwuusquHED .mקEq=^ˣb O ㄢ(FwII^1-ytCi%x FtB4GoE$ohO+cD|n>fcˌ0G,aIlb90#0ʱ l{_r6D1nc